Kither Biotech is a biopharma company founded by Prof. Emilio Hirsch, Prof. Alberto Bardelli and Marco Kevin Malisani. The company aims to identify and develop new drug candidates for the treatment of pulmonary diseases, with specific focus on cystic fibrosis and idiopathic pulmonary fibrosis. Kither Biotech is a spin-off from the University of Turin and actively collaborates with the Molecular Biotechnology Center (University of Turin) and other research centres in the world. The company developed a pipeline of treatments currently under preclinical development, with programs in cystic fibrosis, asthma, COPD, idiopathic pulmonary fibrosis and other therapeutic areas. |
Location: Italy, Piemont, Turin
Employees: 11-50
Total raised: $26.74M
Founded date: 2011
Investors 5
| Date | Name | Website |
| - | Italian An... | italianang... |
| - | CDP Ventur... | en.cdpvent... |
| - | Club degli... | clubdeglin... |
| - | 3B Future ... | 3bfuturehe... |
| - | Elysia Cap... | elysiacapi... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 29.03.2022 | Series B | $20.44M | - |
| 05.07.2019 | - | $6.31M | - |
Mentions in press and media 7
| Date | Title | Description |
| 22.09.2023 | Can Biopharma Innovations Cure Chronic Inflammatory Diseases? Exploring New EU Treatments | “`html Key Takeaways Kither Biotech is on the cutting edge of biopharma and biotechnology, developing innovative treatments for chronic inflammatory diseases. The company’s main focus is on the development of a small peptide, KIT2014, targ... |
| 29.03.2022 | Kither Biotech Raises €18.5M in Series B Funding | Kither Biotech, a Turin, Italy-based biopharmaceutical company developing novel therapies for rare respiratory diseases, raised €18.5m in Series B financing round. The round was co-led by new investors Claris Ventures and 2 Invest, with par... |
| 17.03.2022 | Kither Biotech closes €18M+ Series B | Kither Biotech has raised €18.5 million in a Series B co-led by Claris Ventures and 2 Invest. The Italian company develops novel treatments for rare respiratory diseases. View round |
| 16.03.2022 | Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer | Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer Proceeds to support the further development of lead asset KIT2014 in cystic fibrosis through to Phase 1/2A clinical trial International... |
| 16.03.2022 | Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer | Turin, Italy, 16 March 2022 Kither Biotech (Kither or the Company), a biopharmaceutical company developing novel therapies for rare respiratory diseases, today announces that it has raised €18.5 million in a Series B financing round and h... |
| 09.07.2019 | Kither Biotech Raises €5.6M in Financing | Kither Biotech, a Turin, Italy-based spin-off company from the University of Turin focusing on the development of new treatments for pulmonary diseases, raised €5.6m in Series A financing round. Backers included Invitalia Ventures, business... |
| 05.07.2019 | Kither Biotech raises a €5.6m financing round to support the clinical development of a new drug | Kither Biotech raises a €5.6m financing round to support the clinical development of a new drug for cystic fibrosis and other pulmonary diseases Kither Biotech, a spin-off company from the University of Turin focusing on the developmen... |